Claritev (CTEV) SVP Tiffani Misencik Sells $138K of Stock

Claritev Corporation NYSE: CTEV insider Tiffani Misencik unloaded 5,812 shares of the company stock on October 15, 2026, according to a Form 4 filing with the SEC.

Inside Tiffani Misencik's Claritev Trade

Misencik, who serves as the SVP and Chief Growth Officer at Claritev, executed the sale through a pre-arranged Rule 10b5-1 trading plan. The shares were sold at an average price of $23.81, for a total value of $138,390.11. On the day of the transaction, Claritev stock closed at $23.86.

Other Institutional Activity in Claritev Corporation

Large financial funds hold significant stakes in the healthcare technology firm, with several major holders reporting positions recently. H&F Corporate Investors VIII, Ltd. held 3,887,858 shares valued at about $85,999,422. Ares Management LLC maintained its position of 1,863,105 shares worth roughly $41,211,884. Arini Capital Management Ltd held 1,534,687 shares valued at $33,947,277, while Public Investment Fund reported 1,281,250 shares worth $28,341,251. Beach Point Capital Management LP trimmed its holdings by 24,735 shares, ending with 770,612 shares valued at about $17,045,938.

Claritev Corporation Stock Down 7.8%

Shares of Claritev recently traded around $21.99 as of October 16, 2026. The stock sits below its 50-day and 200-day moving averages, and well off its 52-week high of $73.68.

Recent Earnings

For the trailing twelve months, Claritev reported $994.67 million in revenue and a negative basic earnings per share of $17.00, alongside a net margin of -28.5%. The company is scheduled to report its next set of financial results on November 9, 2026.

Dividend

Claritev Corporation does not currently pay a dividend to shareholders, retaining its earnings to fund ongoing operations and growth in its cost management and revenue integrity software.

Insider Buying and Selling at Claritev Corporation

Insider transactions at the firm have included multiple moves in recent months. Earlier, on August 14, 2026, Tiffani Misencik sold 8,850 shares at an average price of $40.07 for a total of $354,593. Later in the month, CEO Travis Dalton purchased 6,450 shares worth $249,664 on August 28, 2026. CFO Douglas Michael Garis then sold 9,025 shares for $276,075 on September 21, 2026.

Analysts Set New Price Targets

Wall Street firms covering the stock have updated their outlooks through the summer. Canaccord Genuity maintained a Buy rating while lifting its target to $37.00 on July 21, 2026, and later raised it to $43.00 on August 10, 2026. Citigroup maintained a Buy rating and increased its target to $45.00 on August 10, 2026. Wells Fargo maintained an Equal-Weight rating with a $30.00 target on August 12, 2026, and Barclays maintained an Overweight rating with a $40.00 target on August 21, 2026. The stock carries a consensus Buy rating and an average price target of $46.00 across five analyst opinions.

About Claritev Corporation

Claritev Corporation builds data analytics and technology platforms designed to help healthcare organizations manage costs, handle payments, and maintain revenue integrity. Headquartered in McLean, Virginia, the company employs approximately 3,000 people and serves the U.S. healthcare sector with specialized software solutions.

Bottom Line

Investors will look toward the upcoming earnings release on November 9, 2026, for further updates on the company's financial direction. Form 4 filings will continue to track executive buying and selling activity as shares trade ahead of the report.